1. AB0323 Weekly subcutaneous abatacept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading dose. (23rd January 2014) Authors: Schiff, M.; Alten, R.; Weinblatt, M.; Nash, P.; Fleischmann, R.; Durez, P.; Kaine, J.; Delaet, I.; Kelly, S.; Maldonado, M.; Patel, S.; Genovese, M. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A886 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0553 Switching from SC to IV abatacept: Pharmacokinetic simulations to support dose regimen. (23rd January 2014) Authors: Tagen, M.; Murthy, B.; Delaet, I.; Karyekar, C.; Roy, A. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 670 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0567 Safety of SC abatacept in patients with ra: Update from pooled clinical trial data. (23rd January 2014) Authors: Alten, R.; Kaine, J.; Keystone, E.; Nash, P.; Delaet, I.; Qi, K.; Genovese, M.C. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 670 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0191 Immunogenicity is low and transient with intravenous abatacept therapy. (23rd January 2014) Authors: Weinblatt, M.E.; Genovese, M.C.; Schiff, M.H.; Westhovens, R.; Alten, R.; Delaet, I.; Nys, M.; Manning, J.; Kremer, J.M. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0193 SC vs IV abatacept in RA: post-hoc efficacy analysis of long-term acquire (SC) data with aim (IV) data. (23rd January 2014) Authors: Genovese, M.; Pacheco Tena, C.; Covarrubias Cobos, A.; Leon, G.; Mysler, E.F.; Keiserman, M.; Valente, R.; Nash, P.; Simon Campos, J.A.; Box, J.; Legerton, C.W.; Nasonov, E.; Durez, P.; Delaet, I.; Elegbe, A.; Alten, R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0128 Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data. (23rd January 2014) Authors: Alten, R.; Hochberg, M. C.; Cohen, R. B.; Weinblatt, M. E.; Kaine, J.; Keystone, E.; Nash, P.; Delaet, I.; Genovese, M. C. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A624 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0246 Subcutaneous Abatacept: Long-Term Data From the Acquire Trial. (23rd January 2014) Authors: Alten, R.; Pacheco-Tena, C.; Covarrubias, A.; Leon, G.; Mysler, E.; Keiserman, M.; Valente, R.; Nash, P.; Simon-Campos, J.; Box, J.; Legerton, C.; Nasonov, E.; Durez, P.; Delaet, I.; Genovese, M. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗